Ischemia and reperfusion (I/R) injury is a major cause of morbidity and mortality in various diseases, including myocardial infarction, stroke, acute kidney injury, and trauma. I/R injury occurs when blood flow is restored to an ischemic organ, leading to tissue damage and inflammation. The mechanisms of I/R injury involve metabolic imbalance, immune activation, and cell death programs. Recent advances in understanding the molecular and immunological pathways of I/R have led to the development of innovative therapeutic strategies. I/R injury is characterized by a sterile inflammatory response, involving pattern-recognition receptors such as TLRs, immune cell activation, and complement system activation. TLR4 signaling is implicated in I/R injury, and inhibitors of TLR signaling are being developed as potential therapies. Innate immune responses, including the activation of neutrophils and macrophages, contribute to tissue damage. Adaptive immune responses, particularly the role of γδ T cells in producing IL-17, are also involved in I/R injury. Regulatory T cells (Treg) may have a protective role in I/R injury. Complement system activation, platelet aggregation, and coagulation contribute to I/R injury. Autophagy and cell death programs, including apoptosis and necrosis, are also involved in I/R injury. Therapeutic approaches to enhance ischemia tolerance include ischemic conditioning, metabolic strategies, and therapeutic gases such as hydrogen, nitric oxide, hydrogen sulfide, and carbon monoxide. Nucleotide and nucleoside signaling, including ATP and adenosine, play a role in I/R injury. MicroRNAs (miRNAs) are emerging as potential therapeutic targets for I/R injury. Despite progress in understanding I/R injury, challenges remain in translating these findings into effective therapies. Clinical trials are ongoing to evaluate the safety and efficacy of various therapeutic approaches for I/R injury. The development of new therapies for I/R injury is an important area of research with potential to improve patient outcomes.Ischemia and reperfusion (I/R) injury is a major cause of morbidity and mortality in various diseases, including myocardial infarction, stroke, acute kidney injury, and trauma. I/R injury occurs when blood flow is restored to an ischemic organ, leading to tissue damage and inflammation. The mechanisms of I/R injury involve metabolic imbalance, immune activation, and cell death programs. Recent advances in understanding the molecular and immunological pathways of I/R have led to the development of innovative therapeutic strategies. I/R injury is characterized by a sterile inflammatory response, involving pattern-recognition receptors such as TLRs, immune cell activation, and complement system activation. TLR4 signaling is implicated in I/R injury, and inhibitors of TLR signaling are being developed as potential therapies. Innate immune responses, including the activation of neutrophils and macrophages, contribute to tissue damage. Adaptive immune responses, particularly the role of γδ T cells in producing IL-17, are also involved in I/R injury. Regulatory T cells (Treg) may have a protective role in I/R injury. Complement system activation, platelet aggregation, and coagulation contribute to I/R injury. Autophagy and cell death programs, including apoptosis and necrosis, are also involved in I/R injury. Therapeutic approaches to enhance ischemia tolerance include ischemic conditioning, metabolic strategies, and therapeutic gases such as hydrogen, nitric oxide, hydrogen sulfide, and carbon monoxide. Nucleotide and nucleoside signaling, including ATP and adenosine, play a role in I/R injury. MicroRNAs (miRNAs) are emerging as potential therapeutic targets for I/R injury. Despite progress in understanding I/R injury, challenges remain in translating these findings into effective therapies. Clinical trials are ongoing to evaluate the safety and efficacy of various therapeutic approaches for I/R injury. The development of new therapies for I/R injury is an important area of research with potential to improve patient outcomes.